{
    "nctId": "NCT02534129",
    "briefTitle": "Topical Use of Difinsa53\u2122 to Prevent Radiation Dermatitis",
    "officialTitle": "Topical Use of a Silibin-based Cream, Difinsa53\u2122, to Prevent Radiation Dermatitis in Patients With Breast Cancer: A Prospective Study",
    "overallStatus": "TERMINATED",
    "conditions": "Radiodermatitis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 13,
    "primaryOutcomeMeasure": "Radiation Dermatitis as Determined by Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients 18 years and older\n* Pathologic diagnosis of breast cancer requiring radiation therapy to whole breast\n* Able to apply lotion to treatment area at least twice daily during radiation course\n* All surgical sites healed\n* No evidence of infection\n* No history of sensitivity to any component in Aquaphor or Difensa53\n\nExclusion Criteria:\n\n* Prior history of radiation therapy (RT) to that site\n* Known dermatologic conditions affecting skin in radiation port\n* Concurrent chemotherapy\n* Skin infection in radiation port\n* History of sensitivity to Aquaphor or Difensa53 component",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}